NcXHF

OVERCOMING RESISTANCE TO ANTI-EGFR THERAPY IN COLORECTAL CANCER
combination in patients (pts) with BRAF V600E mutated colorectal
cancer (CRC). J Clin Oncol. 2014;32:5s (suppl; abstr 3515).
19. Tabernero J, van Geel R, Bendell JC, et al. Phase I study of the selective
BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab
and with or without the a -specifıc PI3K inhibitor alpelisib (BYL719) in
patients with advanced BRAF mutant colorectal cancer. Eur J Cancer.
2014;50 (suppl 6; abstr 11LBA).
20. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF,
and EGFR status in determining benefıt from cetuximab therapy in
wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924-
5930.
21. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation
contributes to impaired responses to cetuximab in metastatic colorectal
cancer patients. Ann Oncol. 2009;20:84-90.
22. Tian S, Simon I, Moreno V, et al. A combined oncogenic pathway signature
of BRAF, KRAS and PI3KCA mutation improves colorectal cancer
classifıcation and cetuximab treatment prediction. Gut. 2013;62:
540-549.
23. Valtorta E, Misale S, Sartore-Bianchi A, et al. KRAS gene amplifıcation
in colorectal cancer and impact on response to EGFR-targeted therapy.
Int J Cancer. 2013;133:1259-1265.
24. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling
causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Sci Transl Med. 2011;3:99ra86.
25. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform
of patient-derived xenografts (xenopatients) identifıes HER2 as an
effective therapeutic target in cetuximab-resistant colorectal cancer.
Cancer Discov. 2011;1:508-523.
26. Bardelli A, Corso S, Bertotti A, et al. Amplifıcation of the MET receptor
drives resistance to anti-EGFR therapies in colorectal cancer. Cancer
Discov. 2013;3:658-673.
27. Huang S, Li C, Armstrong EA, et al. Dual targeting of EGFR and HER3
with MEHD7945A overcomes acquired resistance to EGFR inhibitors
and radiation. Cancer Res. 2013;73:824-833.
28. Kawakami H, Okamoto I, Yonesaka K, et al. The anti-HER3 antibody
patritumab abrogates cetuximab resistance mediated by heregulin in
colorectal cancer cells. Oncotarget. 2014;5:11847-11856.
29. Cushman S, Jiang C, Hatch A, et al. Gene expression markers of effıcacy
and resistance to cetuximab treatment in metastatic colorectal
cancer: results from CALGB 80203 (Alliance). Clin Cancer Res. Epub
2014 Dec 17.
30. Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal
cancer cells from EGFR inhibition via MET activation. Clin Cancer
Res. 2011;17:472-482.
31. Luraghi P, Reato G, Cipriano E, et al. MET signaling in colon cancer
stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer
Res. 2014;74:1857-1869.
32. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis
of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;
30:2956-2962.
33. Siu LL, Shapiro JD, Jonker DJ, et al. Phase III randomized, placebocontrolled
study of cetuximab plus brivanib alaninate versus cetuximab
plus placebo in patients with metastatic, chemotherapy-refractory,
wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group
and AGITG CO.20 Trial. J Clin Oncol. 2013;31:2477-2484.
34. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab
in metastatic colorectal cancer. N Engl J Med. 2009;360:563-
572.
35. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of
chemotherapy, bevacizumab, and panitumumab compared with chemotherapy
and bevacizumab alone for metastatic colorectal cancer.
J Clin Oncol. 2009;27:672-680.
36. Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal
growth factor receptor using the combination of cetuximab and erlotinib:
preclinical evaluation and results of the phase II DUX study in
chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol.
2012;30:1505-1512.
37. Van Cutsem E, Eng C, Nowara E, et al. Randomized phase Ib/II trial of
rilotumumab or ganitumab with panitumumab versus panitumumab
alone in patients with wild-type KRAS metastatic colorectal cancer. Clin
Cancer Res. 2014;20:4240-4250.
38. Tamayo ME, Cornelio GH, Bautista JB, et al. Safety and effıcacy of Imprime
PGG plus cetuximab with irinotecan and without irinotecan in
patients with advanced colorectal cancer (CRC): a phase 1b/2 study with
KRAS subpopulation analysis. Ann Oncol. 2010;21 (suppl 6; abstr
PD0009).
39. Perez EA, Thompson EA, Ballman KV, et al. Genomic analysis reveals
that immune function genes are strongly linked to clinical outcome in
the North Central Cancer Treatment Group N9831 adjuvant trastuzumab
trial. J Clin Oncol. Epub 2015 Jan 20.
40. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and
acquired resistance to anti-EGFR therapy in colorectal cancer. Nature.
2012;486:532-536.
41. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor
DNA in early- and late-stage human malignancies. Sci Transl Med.
2014;6:224ra24.
42. Arena S, Bellosillo B, Siravegna G, et al. Emergence of multiple EGFR
extracellular mutations during cetuximab treatment in colorectal cancer.
Clin Cancer Res. Epub 2015 Jan 27.
43. Diaz LA Jr., Williams RT, Wu J, et al. The molecular evolution of acquired
resistance to targeted EGFR blockade in colorectal cancers. Nature.
2012;486:537-540.
44. Montagut C, Bellosillo B, Gonzalez I, et al. Evolution of heterogeneous
mechanisms of acquired resistance to cetuximab-based therapy in colorectal
cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 3526).
45. Troiani T, Martinelli E, Napolitano S, et al. Increased TGF-alpha as a
mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab
through EGFR-MET interaction and activation of MET signaling
in colon cancer cells. Clin Cancer Res. 2013;19:6751-6765.
46. Montagut C, Dalmases A, Bellosillo B, et al. Identifıcation of a mutation
in the extracellular domain of the epidermal growth factor receptor conferring
cetuximab resistance in colorectal cancer. Nat Med. 2012;18:
221-223.
47. Price TJ, Newhall J, Peeters M, et al. Prevalence and outcomes of patients
(pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab
(pmab) vs. cetuximab (cmab) in pts with chemorefractory
wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol.
2015;33 (suppl 3; abstr 740).
48. Iida M, Brand TM, Starr MM, et al. Sym004, a novel EGFR antibody
mixture, can overcome acquired resistance to cetuximab. Neoplasia.
2013;15:1196-1206.
49. Hobor S, Van Emburgh BO, Crowley E, et al. TGF alpha and amphiregulin
paracrine network promotes resistance to EGFR blockade in
colorectal cancer cells. Clin Cancer Res. 2014;20:6429-6438.
50. Wadlow RC, Hezel AF, Abrams TA, et al. Panitumumab in patients with
KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist.
2012;17:14.
51. Saif MW, Kaley K, Chu E, et al. Safety and effıcacy of panitumumab
therapy after progression with cetuximab: experience at two institutions.
Clin Colorectal Cancer. 2010;9:315-318.
52. Paz-Ares LG, Gomez-Roca C, Delord JP, et al. Phase I pharmacokinetic
and pharmacodynamic dose-escalation study of RG7160 (GA201), the
fırst glycoengineered monoclonal antibody against the epidermal growth
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e155